FDA and drug manufacturers have alleviated a critical shortage of the widely used cancer drug methotrexate by identifying new international sources of active pharmaceutical ingredients, but the potential risks of using foreign API makers just a few years after the tainted heparin scandal cannot be far from anyone’s thoughts.
FDA Commissioner Margaret Hamburg announced at a Feb
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?